Eleftherios Zografos

Model‐Based Meta‐Analysis of Objective Response Rate and Survival Endpoints to Compare PD ‐1 and PD ‐ L1 Treatment Outcomes in Non‐Small Cell Lung Cancer

Richard C. Franzese, Li Qin, Shuai Fu, Benjamin E. Rich et autres

Programmed cell death (PD) protein (ligand [L])-1 inhibitors are established treatments for metastatic non-small cell lung cancer (mNSCLC). In oncology, progression-free survival (PFS) and objective response rate (ORR) are often used as surrogates for overall survival (OS) to inform clinical development; however, …

gb, us (code pays fourni par la source)

Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

This includes supplementary tables and figures

A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".

Mansoor R. Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen et autres

WHAT IS THIS SUMMARY ABOUT? Dostarlimab, also known by the brand name JEMPERLI, is a medicine that uses a patient's own immune system to treat endometrial cancer. Dostarlimab is a type of medicine called an immunotherapy. Immunotherapies help the immune system find …

dk, us, hu, ca, it, de, nl, fi, cz (code pays fourni par la source)

Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

This includes supplementary tables and figures

Data from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

Abstract Purpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Patients and Methods: A total of 153 …

Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

This includes supplementary tables and figures

945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)

J-P. Machiels, Barbara Burtness, Kevin J. Harrington, Nabil F. Saba et autres

be (code pays fourni par la source)

Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

This includes supplementary tables and figures

Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

This includes supplementary tables and figures

Data from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier et autres

AbstractPurpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Patients and Methods: A total of 153 patients …

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto et autres

Abstract PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable genomic aberrations. Patients …

kr, ch, es, br, it, ro, de, gb, us (code pays fourni par la source)

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier et autres

Importance: Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor. Objective: To assess the antitumor activity and safety of dostarlimab in patients …

fr, it, es, ca, gb, us (code pays fourni par la source)